MedPath

Effect of pilocarpine 2% eye drops on treatment resistant oral erosions of pemphigus.

Phase 3
Completed
Conditions
Health Condition 1: null- recalcitrant oral ulcers of pemphigus vulgaris
Registration Number
CTRI/2017/11/010445
Lead Sponsor
IADV
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

2.Refractory oral PV, arbitrarily defined for present study as less than 75% reduction in ABSIS score after being treated with optimum systemic and topical treatment for 6 months; with lesions at sites accessible to topical pilocarpine application including retro-molar trigone, buccal mucosa, gingiva and palate.

Twenty PV patients satisfying above-mentioned inclusion criteria will be recruited for this pilot study

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary aim of present study is to assess the efficacy and safety of topical pilocarpine 2% eye-drops (in terms of reduction in the size of erosions) in treatment of refractory/ persistent oral lesions of pemphigus vulgaris (PV) situated on buccal mucosa, retro-molar trigone, gingiva and palate. <br/ ><br> <br/ ><br>Also, measurement of anti desmoglein 1 and 3 antibodies will be done in both saliva and serum, at the time of inclusion in study and after completion of treatment.Timepoint: 6 months
Secondary Outcome Measures
NameTimeMethod
Secondary aim is to assess the effect of pilocarpine application on subjective improvement and quality of life as experienced by the patient (using VAS and OHIP-14 scoring).Timepoint: 6 months
© Copyright 2025. All Rights Reserved by MedPath